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Abstract: An examination of the current system of intellectual property law and 
the application of the Rawlsian methodology of justice to evaluate the current 
pharmaceutical patent system.  The Thesis then explores the Health Impact 
Fund’s proposed new system to fund pharmaceutical research, which is also 
applied to the Rawlsian methodology.  The merits of the recent proposal are 
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Introduction 
 In this thesis I examine the current system of intellectual property law as it 
concerns patents for pharmaceuticals. My aim is to show that the present 
system, while having many virtues, provides incentives which skew the resources 
used to develop new medications in a way that results in fewer of those 
resources being devoted to developing medications that would most help those 
who need them most, the poor people in the world’s developing countries. But I 
am not solely concerned to point out an injustice that results from the present 
structure of patent law. I also examine the merits of a recent proposal to alleviate 
some of the existing system’s flaws.  
 I begin by outlining a methodology developed by John Rawls for 
formulating principles of justice for the basic structure of a developed society. I 
show that this methodology—which focuses our attention on fairness—is (duly 
modified) an appropriate methodology for evaluating how just our present patent 
system is and for helping us modify it in ways that would make it more just, or at 
least less unjust. I then give a sketch of the current patent system. Following that, 
I point out the virtues and vices of the existing system and raise the question of 
how we might retain the former while reducing the latter. Because the 
development of new pharmaceuticals has in general been a great benefit to 
mankind, it is something that we ought to devote adequate resources to 
furthering research in this field. Unfortunately, such research and development is 
quite expensive. Therefore, I briefly examine the three most obvious ways in 
which such research might be funded; through charity, government funding and 
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through patents.  Following that, I examine how from a Rawlsian point of view 
one would examine the current patent system and in what ways it is unjust.  I will 
provide a number of statistics, which are supportive of the Rawlsian conclusion 
that the current patent system is unjust and pose some possible solutions to 
these tribulations.  I will then briefly describe the Health Impact Fund proposal.  I 
will employ the modified version of the Rawlsian methodology described earlier 
to evaluate the justice of the Health Impact Fund.  I am able to show that, from 
the Rawlsian perspective, the Health Impact Fund proposal, if adopted would be 
one of the most just systems to fund pharmaceutical research and development 
that could improve the health of poor people in developing countries, and on a 
global scale.   
The Rawlsian Methodology 
In this thesis the major issue involves justice and international 
development.  In his important works, A Theory of Justice and The Law of 
Peoples John Rawls developed a methodology, which I will refer to as the 
Rawlsian methodology, for developing principles of justice for both individual 
societies and for relations between societies. I will be using this Rawlsian 
methodology to determine what justice would require in instances of international 
relations, and in particular the issues which I am dealing with in this thesis, 
international patent law as it concerns pharmaceuticals.  Rawls illustrates that 
justice requires fairness or that thinking about fairness helps us when deciding on 
principles of justice.  
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 The starting point for Rawls’s theory of justice is the original position.  In 
this original position people are situated behind what Rawls calls a veil of 
ignorance.   Individuals who are rational and only concerned with their own 
interests but who are ignorant of their own identity are asked to choose principles 
of justice to govern all members of their society.  Behind the veil of ignorance one 
would not know if they are male or female, which race they are, if they are 
educated or not, or which religion they practice, along with many other variables.  
The individuals behind the veil of ignorance know the general facts about the way 
the world works, such as the basic needs humans require, and about the society 
in which they will be living.  When a person is rational and self-interested, that is 
to say they are driven to select in an informed manner, they would choose 
whatever would seem advantageous to them.  However, Rawls argues that 
people who find themselves in the special circumstances of the original position 
will be particularly concerned with the situation of those considered worst off in 
society. Because of this concern with the possibility that one might find, upon 
lifting the veil of ignorance, that one was among the worst off individuals, Rawls 
argues that when deciding on principles of justice for society it is rational to 
employ the maximin decision rule.  When using the maximin decision rule one 
pays particular attention to the worst possible outcomes when making decisions 
under uncertainty. Indeed, the maximin rule requires one to rank alternatives 
based on their worst outcomes and choose the alternative that has the best worst 
outcome. This provides some kind of insurance in case the person behind the 
veil of ignorance is in fact a member of the worst off in society; they have made 
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their position the best it could be.  Rawls claims that when behind the veil of 
ignorance individuals will choose his two principles of justice as the basic 
principles for their society.   
Rawls decides on two basic principles of justice, which are the principle of 
equal liberty and the difference principle.  The principle of equal liberty is 
concerned with the distribution of basic liberties and should be used when 
designing the political institutions of society and applies to all citizens.  Each 
member of society should have the most extensive set of liberties compatible 
with the same liberties for all.  The difference principle applies primarily to 
economic institutions and is the principle of distributive justice.  According to the 
difference principle social and economic inequalities should be arranged so that 
they work to the greatest benefit of the least advantaged in society. This is 
usually thought to require having goods and services distributed equally unless 
an unequal distribution would benefit those worst off in society.  The difference 
principle may mean a society will implement projects that require giving some 
more power, status, and income if in turn it raises the living standards of 
everyone in the community or in any way make life better off for those in the 
worst off position in the society.  These principles, when chosen behind a veil of 
ignorance, leave no room—or as little room as possible for humans with limited 
imaginative capacities—for biases or for unfairness to be present.   Both the 
	   7	  
individuals and the situation Rawls describes are designed to reflect the 
fundamental characteristics and principles we think justice should have. 1  
Description of the Current Patent System 
 A patent is a form of intellectual property.  Exclusive rights are granted to 
an inventor or company by the state for a limited period of time. These exclusive 
rights include the sole right to make, use, and sell the invention.  In return for 
these rights the inventor gives the government a complete description of their 
invention.  According to the Canadian Intellectual Property Office (CIPO), this 
description received from the inventor is made public in Canada so that all 
Canadians can benefit from the advance in technology the invention provides. In 
Canada, the protection lasts for twenty years from the date that the patent 
application is filed, as long as the required fees are paid.2  If an inventor receives 
a patent in Canada the sole right to use, make and sell the invention are only 
guaranteed in Canada.  To make these rights valid in another country the 
inventor would have to apply for and acquire a patent in that country.  Patents 
can only be applied for in the name of the actual inventor.  In order to apply for a 
patent the invention needs to be new, nonobvious or useful.  For example, a 
process, machine, article of manufacture, composition of matter, or an 
improvement on any of the previously mentioned are all things that can acquire a 
patent, if applied for by the inventor according to The United States Patent and 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
1	  For a more detailed account of the matters discussed in this section see 
<http://people.wku.edu/jan.garrett/ethics/johnrawl.htm#prin> 
 
2 Canadian Intellectual Property Office, “What is a Patent?” 
2011<http://www.cipo.ic.gc.ca/eic/site/cipointernet-
internetopic.nsf/eng/wr01400.html>	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Trademark Office.  The types of objects or phenomena that cannot be patented 
are things such as laws of nature, physical phenomena, abstract ideas, 
inventions that are not useful or are offensive to public morality. Literary, musical 
and dramatic works cannot be patented although they can be copyrighted.3  
 There are several reasons why an inventor may want to obtain a patent.  
Patents can provide the possibility of protecting and keeping exclusive 
commercially important technology.  A company or individual would want 
exclusive rights to be the sole maker, user, and seller of an invention or 
technology to improve their market position.  It provides the possibility of holding 
a monopoly in the marketplace until the patent expires. Having a patent on an 
invention does not guarantee that it will be commercially successful. Holding a 
patent on something provides the chance of a better market position, it gives 
inventors the chance to prevent others from benefitting from their ingenuity, and it 
prevents others from receiving some of the profits from the invention without the 
patent holders permission.  Not only does the patent supply the rights to the 
inventor as sole maker, user, and seller but also as sole beneficiary as far as 
profits are concerned.   
 Patents are enforced by National Patent Offices, the World Trade 
Organization (WTO), and evaluated by the World Intellectual Property 
Organization (WIPO).  National Patent Offices are government organizations that 
take care of all issues surrounding patents from the application process to 
enforcing restrictions when patents are acquired.  The WTO gives patent 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
3	  The United States Patent and Trademark Office, “What Can and Cannot be 
Patented?” 2013<http://www.uspto.gov/inventors/patents.jsp>	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protection on a larger global scale and adopted the Agreement on Trade Related 
Aspects of Intellectual Property Rights (TRIPS).  WIPO is a United Nations 
Agency that administers global intellectual property treaties.  These organizations 
provide patent protection to those seeking it by giving judicial enforcement of the 
intellectual property rights.  If a company thinks that their patent rights have been 
violated they are able to sue the violator(s) and their National Patent Office would 
be able to provide official documents to show ownership of the intellectual 
property.4 5 
 The current patent system provides certain advantages to the research 
and development process.   It also includes certain complications or features, 
which have created a system that is in some ways both inefficient and biased. 
There is the possibility of a system that could produce better results in the 
pharmaceutical industry over the current patent system. When examining the 
pros and cons of the existing pharmaceutical patent system we need to consider 
both how it affects the patent holders and additionally how it affects people who 
need the drugs that have been patented. We need to consider not just those who 
now consume patented drugs, but also those who might consume drugs had the 
system been different and resulted in other drugs being developed. Put another 
way, we need to look at the issue on a global scale and consider all the 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
4 O.A. Thusleem, “The Global Institutions Responsible for Administering the 
Patent System,” 2008 <http://www.pharmainfo.net/reviews/patent-system-
pharmaceutical-industry> 
5 For more information on Intellectual Property Rights see  
http://users.wfu.edu/mcfallta/DIR0/pharma_patents.pdf	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possibilities that our greatly expanding knowledge of how to use chemical means 
to enhance human health can best be used to serve all peoples.   
 For the patent holders there are more positive than negative outcomes 
when using the current patent system.  The current patent system keeps others 
out of the market, puts restrictions on competitors, generates revenue from 
licenses and sales, gives the patent holder the right to practice the invention, 
gives their product credibility, and gives the patent holder the future possibility of 
marketing themselves to a future employer.  When an inventor acquires a patent 
that gives them the right to exclude others from producing, using, selling, as well 
as importing and exporting their invention for the length of the patent it keeps 
others out of the market which can be extremely valuable.  This could be 
considered a government-granted monopoly.  The standard justification for the 
system of patents is that government grants patents for the purpose of bettering 
society in the long run by creating incentive for innovation.  After the patents 
expire, society will have free access to the new technologies.  When it comes to 
putting restrictions on competitors, an inventor may come up with a new 
technology for a specific industry and patent that idea however; they might not be 
able to practice their idea if it infringes on another competitor’s patent.  It is 
possible to patent an idea before current restrictions of producing and 
manufacturing are lifted.  This restricts a company’s competitors by obtaining the 
patent for the new technology, regardless of being able to produce the invention.  
When the competitor’s patent expires the inventor will be able to practice the new 
invention.  Patent holders make their profit from selling the patented product but 
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another profitable practice is to license the technology to others.  It is common for 
a person licensing to pay an initial fee plus royalties.  Another possibility is to sell 
a patent for the remaining time it is in place.  A patent is a safe way to prevent 
another company from producing or selling an invention belonging to the patent 
holder during the time the patent is in place.   
 There are few negative components to patenting a product for the patent 
holder.  What might be a problem for the patent holder is the cost and liability.  
Patents do not only involve the initial application fee but a filing fee, and issue 
fee, as well as maintenance fees throughout the length of the granted patent.  
The prices of these fees vary with the size of the business with larger businesses 
paying more than the smaller businesses.  The liabilities associated with patents 
and the possible lawsuits are other downsides.  Competitors may try and 
overturn a patent if there are great profits in the balance.6  
 The current patent system facilitates positive and negative elements for 
humans on a global scale just as it does for the patent holders. The 
pharmaceutical industry’s current patent system will have a more pronounced 
impact for humankind on a global scale rather than on the patent holders.  In this 
case, it is not just profits to consider but better health and quality of life for 
humans.  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
6 Inventor Basics, “Patent Pros and Cons” 2011 
<http://www.inventorbasics.com/Patent%20Pros%20&%20Cons.htm> 
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Josh Bloom7, a physician, and Gregory J. Glover8, an attorney who 
specializes in competition in the pharmaceutical industry and intellectual 
property, argue that a crucial part of the drug development cycle includes the 
importance of maintaining incentives for pharmaceutical research.  They believe 
intellectual property rights and patents create this incentive.  Achieving the 
promise of pharmaceutical innovation requires the upkeep of strong and 
foreseeable intellectual property rights. The social value of the pharmaceutical 
industry is apparent and profound.  Not only are patents the source of cost 
effective treatments that continue to increase life expectancy and improve the 
quality of life, it is also a significant contributor to the strength of the first world 
economy.  Strong intellectual property protection is essential to a vital innovative 
pharmaceutical industry. The strength of intellectual property rights protection 
greatly impacts investment decisions. This investment is essential to enable 
further pharmaceutical innovation as well as promote competition in the industry.  
In short, without the current patent system there is little incentive for 
pharmaceutical industries to develop new drugs, unless they are drugs for people 
who are willing and able to pay the substantial costs of developing and patenting 
such drugs.  When looking at the patent system strictly as a business, one would 
be able to conclude that the pharmaceutical industry is a successful industry, 
however, this is not taking into consideration global health.     
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
7 Josh Bloom, “Yes: Innovation Demands it” 2012 
<http://online.wsj.com/article/SB100014240529702045424045771569931916550
00.html> 
8 Gregory J. Glover, “Competition in the Pharmaceutical Marketplace” 2002 
<http://www.ftc.gov/opp/intellect/020319gregoryjglover.pdf>	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Research and Development 
 Research and development refers to specific practices or certain activities 
usually performed by a business.  Research and development practices and 
objectives vary from company to company.  There are two basic models of 
research and development.  In the first model, the primary purpose of a research 
and development group is to come up with new products.  In the second model, 
the purpose of research and development groups is to discover and create new 
knowledge about scientific and technological topics for the purpose of enabling or 
further advancing the development of valuable new products, processes, and 
services.  Research and development activities are typically carried out by 
corporate or government entities.9  
The pharmaceutical industry develops, produces and markets drugs or 
pharmaceutical products that are licensed for use as medications.10  This 
industry is made up of many different companies of all sizes, all of which are 
subjected to a variety of laws and regulations including patents, testing and 
safety, and laws regarding the marketing of the drugs.  Pharmaceutical 
companies are similar to other businesses in that they manufacture products that 
are to be sold for profit in order for that business to survive, grow, and generate 
profits for their shareholders.   
 What makes the pharmaceutical industry different than other industries is 
that the drug business is involved in producing medicines that directly affects the 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
9 Wikipedia, “Research and Development” 2013 
<http://en.wikipedia.org/wiki/Research_and_development> 
10 Science Daily, “Pharmaceutical Company” 2012 
<http://www.sciencedaily.com/articles/p/pharmaceutical_company.htm>	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quality of life for humans and the pharmaceutical industry is very risky.  What 
makes this business risky is that the cost of research, development and 
innovation is very high.  Only one out of every ten thousand discovered 
compounds actually becomes an approved drug able to be marketed and sold for 
profit. Each drug that comes to market has to yield sufficient income not just to 
fund its development but also to fund the development of the thousands of failed 
compounds, which were looked at on the way to finding the successful drug.  On 
average only 3 out of 20 already approved drugs bring in enough revenue to 
cover the cost of research and development.11  The early phases of drug 
development require the majority of investment and funds allocated to 
pharmaceutical innovation.  Unless it is believed that the drug will bring in 
millions or billions of dollars, it will not be profitable to develop.  In order for a 
drug company to survive it would need to discover a “blockbuster” drug every few 
years.  A “blockbuster” drug is an extremely popular drug that generates annual 
sales of at least one billion dollars for the company that discovers and creates 
it.12  Examples of blockbuster drugs include Lipitor and Zoloft.  Blockbuster drugs 
are typically used to treat more common medical problems found in the 
developed world such as high cholesterol, diabetes, high blood pressure, anxiety 
and asthma.    
 Government appointed medical institutions or boards are responsible for 
approving drugs developed by pharmaceutical companies.  Over the past 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
11 Ogbru Omudhome, “Why Drugs Cost So Much,” 2002 
<http://www.medicinenet.com/script/main/art.asp?articlekey=18892> 
12 Investopedia, “Blockbuster Drug,” n.d, 
<http://www.investopedia.com/terms/b/blockbuster-drug.asp>	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decade, the number of drugs approved annually has been within the twenties on 
average.  The approval of a drug only comes after substantial investment in pre-
clinical development and several clinical trials with promising results, along with a 
commitment made by the company for ongoing safety monitoring of the drug.  
   Pharmaceutical companies in Canada and in other key countries play a 
big role in the innovative economy.  Research and development in this sector is 
typically focused on developing the next generation of breakthrough therapies 
and medicines to address unmet medical needs both domestically and globally.  
The Canadian pharmaceutical sector covers the research of new drugs, the 
development, as well as the manufacturing of the developed drugs.13   
 Research and development in the pharmaceutical industry can be funded 
in three different ways; by charities, the government or through patents.  The key 
aim of research charities is to generate knowledge that benefits the public good.  
Charities provide an important independent flow of research funding that 
generally compliments the objectives of the research councils and government 
departments.  In the United Kingdom there are hundreds of research funding 
charities that cover a wide range of objectives.  All of these charities are 
regulated by charity law and are required to follow certain obligations and 
restrictions on the use of charitable funds for research.  For example, there is a 
prohibition on funding research for the purpose of commercial or private gain. In 
the UK the Association of Medical Research Charities (AMRC) is the leading 
member organization that funds medical and health research.  The world’s 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
13 Industry Canada, “Biopharmaceuticals and Pharmaceuticals,” 2012 
<http://www.ic.gc.ca/eic/site/lsg-pdsv.nsf/eng/h_hn01702.html> 
	   16	  
largest charity, The Wellcome Trust is a member as well as over 100 other 
charities.  The common goal of the members of AMRC is improving human 
health by funding a large spectrum of research.  These charities are able to 
provide funding for research in various ways.  A smaller contribution would be a 
one-off grant offered in order to kick-start a particular research project or these 
charities are able to offer substantial funds proposed to fund specific research 
projects.  Medical research charities have some restrictions that only allow them 
to fund research programs that align with their charitable objectives.  This can 
mean that charities may only be able to fund research projects that focus on a 
particular disease, a range of diseases, or a broader objective of improving 
human health through education and research. Research funding charities 
typically are unable to provide as much funding or money as attaining 
pharmaceutical patent would bring forward.    
 Government funding is another way to support research and development 
of pharmaceuticals. Government funding to businesses for research and 
development supports innovation.  Research and development funding is 
provided by the provincial and federal governments in Canada and generally 
takes the form of grants.  In Canada, small and medium innovative enterprises 
are able to apply for or seek government funding and resources if they meet 
certain criteria requirements.  Some of the criteria requires these companies to 
invest at least twenty percent of their total investment into research and 
development.  This government funding provides some incentive for innovative 
companies to invest more into research and development over other activities 
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such as marketing. 14  However, government funding does not provide the 
pharmaceutical companies with an equivalent amount of money to what a patent 
on a successful drug would.   
Companies that develop drugs typically put their money towards 
researching and developing drugs that can foreseeably generate significant 
profits.  The drugs that generally bring about the most profit are those, which 
have a lower impact on global health.  These are drugs that are relevant to the 
developed world where people have money to spend on pharmaceuticals that 
may not be crucial to their health.  People in the developed world have been 
living in a society that teaches them that every slight abnormality they have can 
be treated with a drug.  They are willing and able to pay money for drugs that 
treat non-life threatening symptoms or are common medical problems, such as 
high cholesterol, diabetes, high blood pressure, asthma, and cancer.  Because 
there is such a large market for drugs that treat these common medical problems 
in the developed world, it is a competitive market.  There are generic versions of 
the brand name drugs made once a patent runs out or slight variations of drugs 
are manufactured that treat the same symptoms enabling companies are able to 
enter the market.  A lot of money goes into the research and development of 
“blockbuster drugs” instead of being put towards drugs more relevant to the 
underdeveloped world.  The pharmaceutical industry has a bias towards what 
types of drugs they develop; this bias falls in favour of those who are living in the 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
14 Imperial College London, “Types of Research Funding,” 2013, 
<http://www3.imperial.ac.uk/researchsupport/funderinformation/typesofresearchf
unding> 
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developed world and puts underdeveloped countries at a disadvantage.  Even if 
drugs already exist that treat specific diseases, Big Pharma companies would 
lose money by making available and affordable these drugs to underdeveloped 
countries.  These can and have led to developing countries creating generic 
versions of brand name drugs that will not be made available to them by these 
Big Pharma companies.  This can become a major problem if these countries are 
or eventually become members of the World Trade Organization (WTO).   
For example, Brazil began producing generic versions of HIV/AIDS 
treatments without the permission of the patent holders.  Once the developing 
nations become members of the WTO, they become bound by the organization’s 
intellectual property rights agreements.  In 1994, members of the WTO 
established the Agreement on Trade-Related Aspects of Intellectual Property 
Rights (TRIPS).  A result of TRIPS was the establishment of minimum levels of 
protection for member countries for products including pharmaceuticals. David 
Fidler, an international law professor at Indiana University, believes  “the WTO 
was a game changer”.  If a country wanted the benefits of being a member of the 
WTO they also had to sign TRIPS.  All countries that were members of the WTO 
were granted permission to issue compulsory licenses to produce generic 
versions of products domestically, including pharmaceuticals without the 
permission of the patent holder.  This was allowed only under circumstances of 
national emergency.  However, the compulsory license establishment has led to 
controversy and confusion about how and under what circumstances it should be 
applied.   By 2000, there were a number of cases where emerging economies 
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used the threat to issue compulsory licenses as a tool to influence drug 
negotiations.  This often happened when developing countries were looking for 
HIV/AIDS meds to be made available.  This was somewhat effective because 
drug companies responded by lowering drug prices, sometimes as much as 
40%.  However, a 40% price reduction still did not make drugs affordable for 
those in the developing world.  The compulsory license rule was extended by the 
WTO in 2003 to allow developing countries that do not have the capacity to 
produce their own generic drugs to import them from other countries that are 
operating under a compulsory license.  This further advanced in 2007 when 
Canada became the first country to issue a compulsory license to export generic 
drugs under this rule.  
Seeing as this is one of the only ways a developing country is able to 
provide its citizens with the drugs they require in cases of national emergency to 
combat epidemics, it illustrates how the patent system with respect to 
pharmaceuticals is unjust.  The compulsory license procedure is frowned upon 
by the pharmaceutical industry.  In the view of the industry, the development of 
new drugs depends on the defense of patent rights.  It is also a common belief 
within the pharmaceutical industry that developing countries are able to afford 
these drugs, however, they choose to spend the money elsewhere.  They are 
asserting that drugs are the opportunity cost to spending in other areas.  Some 
pharmaceutical companies use their power to influence developing countries not 
to attain compulsory licenses.  For example, companies will threaten to withhold 
all new drugs they develop from an underdeveloped country if they attain a 
	   20	  
compulsory license.  Although these licenses can be the only hope for a 
developing country to attain required drugs, there can be serious consequences 
for doing so.  This method has been successful in some cases for making drugs 
available to citizens of underdeveloped countries.  It could be anticipated that a 
system which provides an incentive for pharmaceutical companies to make 
available drugs and develop drugs relevant to the developing world would be 
more effective than compulsory licenses.15   
What Makes Pharmaceutical Companies Different Than Other Types of 
Businesses? 
 According to Science Daily a new study developed by two York University 
researchers estimates the US pharmaceutical industry spends almost twice as 
much on promotion and marketing than they spend on research and 
development.16  A common claim made by the pharmaceutical industry is that 
consumers have to pay such high prices for drugs in order to support future 
research and development of new drugs by the companies.  They put forward the 
message that drugs are expensive but that also shows how valuable they are.  
Research-based companies claim that they provide a steady stream of 
innovative drugs that have the potential to lengthen life and enhance its quality; 
they make the impression that the consumers are the beneficiaries and not the 
companies themselves. It rarely gets mentioned the amount of money these 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
15 Toni Johnson, “The Debate Over Generic-Drug Trade,” 2011, 
<http://www.cfr.org/drugs/debate-over-generic-drug-trade/p18055> 
16 York University, “Big Pharma Spends More on Advertising Than Research and 
Development,” 2008, 
<http://www.sciencedaily.com/releases/2008/01/080105140107.htm>	  
	   21	  
companies spend on marketing and promotion, however, what they put forth 
most is the high price of research and development for new drugs.17   
 It would be useful to question the amount of promotion and marketing the 
pharmaceutical industry actually requires in order to stay profitable and in order 
to fund research and development.   The pharmaceutical industry in the United 
States spent $33.5 billion on promotion costs in 2004.18  Compared to other 
types of industries and the type of things they produce, there is a noticeable 
difference in medicines and other consumer products.  Medicines and drugs 
have to do with quality of life and the affordability and availability of these drugs 
can be matters of life and death. The majority of other consumer product 
industries spend significant amounts on marketing and promotion in the United 
States, however, they do not have to do with basic needs, quality of life, or are 
not matters of life or death.  People who have a specific disease will purchase a 
drug designed to cure a disease if it is affordable and available, not because it is 
marketed well.  It seems as though the only drugs that would be beneficial to 
market are those that are referred to as first world “luxury” or “blockbuster” drugs 
that would have a lot of competition.  There is a significant amount of competition 
for these drugs because they are primarily consumed in the first world where 
people have the money to afford them. Companies will make a very similar drug 
that treats the same symptoms as an existing drug in order to get into that 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
17 Marcia Angell, “The Truth About the Drug Companies,” 2004, 
<http://www.nybooks.com/articles/archives/2004/jul/15/the-truth-about-the-drug-
companies/?pagination=false> 
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<http://www.sciencedaily.com/releases/2008/01/080105140107.htm>	  	  
	   22	  
specific market if a profit is to be made.  They create slight variations in the 
existing drug in order to avoid breaking patent laws.  The marketing is required to 
persuade people to buy a certain company’s variation of the drug over another.  
The marketing would not be required in cases for new drug development instead 
of new drug variation.    
 Americans spend $200 billion annually on prescription drugs, however, 
this number is staggering.  This number is growing at a rate of 12% per year, 
down from a high of 18% in 1999.  The increase in drug spending has to do with 
the increase in the consumption of prescription drugs as well as the increase of 
the price of the drugs.  Marcia Angell, former editor of The New England Journal 
of Medicine and current Harvard Medical lecturer believes our society today is 
extremely over-prescribed.  We hold the belief that if there are slight deviations 
from the norm than there is something wrong with us that needs to be fixed.  The 
way we think we can fix these problems are with prescribed medications as 
opposed to changing the behavior and beliefs of society.  We allow the costs of 
these medications to rise because we believe we need them to make a better 
quality of life and to make ourselves more “normal”.   Americans spend $200 
billion on prescription drugs but the pharmaceutical industry is worth much more 
than that.  The global pharmaceutical industry is worth an estimated $400 billion 
dollars.  With this amount of worth comes a great amount of power.19   
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 When an industry is worth as much as the pharmaceutical industry is 
worth, it is a sign of power. The pharmaceutical industry is dealing with life saving 
drugs, and the lives of many people especially in the developing world that are 
depending on their innovation and the availability of drugs they produce.  This 
gives the pharmaceutical industry the potential to make a pronounced impact if 
this power is used in a specific way.  If Big Pharma companies took their profits 
and focused them more towards the research and development of life-
threatening diseases and less towards variations of “blockbuster” drugs there 
would be less of an intention to make great profits and more on curing a broader 
spectrum of diseases.  If this were the main focus then more of an impact would 
be made.  That is not to say that the pharmaceutical industry is not making an 
impact, however, there is the potential for a greater impact to be made that would 
affect the quality of life for humanity as a whole.    
 
Pharmaceutical Patents and Rawlsian Justice 
If one were placed in the Rawlsian original position in order to choose 
what justice would require for the pharmaceutical industry, main concerns would 
lie in accessibility, affordability and improving overall global health.  In this 
position the individual behind the veil of ignorance would be rational and 
concerned with his or her own self-interest, however, they are unaware of their 
identity.  They would not know if they lived in a developed or underdeveloped 
society, if they are wealthy or poor, if they have a certain disease, if the current 
patent system works in their favour and they have drugs available to them at a 
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price they can afford.  If asked to choose principles of justice to govern all 
members of society regarding pharmaceuticals, an individual behind the veil of 
ignorance would be particularly interested in the positions of those considered 
worst off in society.  This is due to the ambiguity of their position in society; there 
is a chance they can find themselves in the worst position in society.   
When talking about pharmaceuticals, the worst position in society would 
be that of an individual with a life-threatening disease, living in an 
underdeveloped country, having no income to pay for medicines, and not have 
drugs be made affordable or accessible to them.  In this position, because 
pharmaceutical companies have biases to developing certain drugs due to the 
current patent system, if the disease this individual has is not relevant to the 
developed world it is likely pharmaceutical spending will not go into researching 
and developing a drug pertaining to that disease.  This is because the drug will 
not generate enough profit for drug companies to want to develop this drug; it 
would not be a good business decision with the current patent system.  Even if a 
drug already exists pertaining to that specific disease, it will not likely be 
accessible to those in the developing world, even if it were affordable, and 
chances are this would not be the case due to high mark-ups pharmaceutical 
companies place on drugs.   
Behind the veil of ignorance, an individual who has the chance of being a 
member of society in the worst position previously described would apply the 
maximin decision rule.  When using the maximin decision rule one would pay 
particular attention to the worst possible outcomes when making decisions under 
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uncertainty; they try to better the positions of those in the worst off positions by 
deciding on principles of justice.  This provides some kind of insurance if the 
person behind the veil of ignorance is in fact a member of the worst off in society; 
they will try and make this position the best it can be.  This means making 
pharmaceuticals affordable and accessible to those in underdeveloped countries, 
but with a system that can keep pharmaceutical companies up and running so 
they are still able to innovate and develop new drugs.   
Rawls claims that individuals behind the veil of ignorance will choose his 
two principles of justice; the principle of equal liberty, and the difference principle.  
The principle of equal liberty refers to distribution of basic liberties and that all 
members of society should have the same liberties.  When talking about the 
global pharmaceutical industry, the society one would be deciding principles of 
justice for would include all humans because it is an issue concerning global 
health.  Principles must be chosen in order to have drugs accessible and 
affordable to all humans.   
According to the difference principle, social and economic inequalities 
should be arranged so that they work to the greatest benefit of the least 
advantaged in society.  When it comes to justice it is usually thought to have 
goods and services distributed equally, unless in this case unequal distribution 
would benefit those worst off in society.  In the circumstance of the 
pharmaceutical industry, it would be more beneficial to have research and 
development focused on diseases that are life threatening and have a higher 
potential for harming humans.  This would mean reversing the current research 
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and development biases and having companies develop drugs for those in the 
underdeveloped world with life-threatening diseases.   
These principles when chosen behind a veil of ignorance leave no room 
for unfairness to be present in the pharmaceutical industry.  The fundamental 
characteristics and principles the pharmaceutical industry should have, in order 
to be considered just can be determined through Rawlsian justice.  Unfortunately, 
the current patent system is not just, and does not include the principles and 
characteristics Rawlsian justice would require.  However, it is possible to create a 
system in which these fundamental characteristics and principles are satisfied.    
How is the Present System Unjust? 
 The main areas where the present patent system falls short according to 
Rawlsian justice and also by Thomas Pogge are in universal access, innovation, 
and overall spending efficiency.  The present patent system provides poor 
universal access to drugs.  There is currently little or no incentive for 
pharmaceutical companies to provide products to poor people in hard to reach 
areas.  People in the developing world are often unable to afford the market price 
of pharmaceutical products.  Consequently, pharmaceutical companies do not 
make the drugs accessible in these developing areas because there is no profit 
to be made by doing this.  Generally drugs are only made available in the 
developed world due to the amount of pharmaceutical consumption and ability of 
people to afford the drugs even with high mark-ups. Pharmaceutical companies 
need to generate large profits in order to fund further research and development 
and to make money for their shareholders.  In order to make drugs more 
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universally accessible, there needs to be an approach that allows pharmaceutical 
companies to stay in business and to provide drugs for the developing world.  
One solution would be to create a system other than the current patent system 
that provides an incentive for companies to innovate and make accessible 
pharmaceutical products pertaining to developing areas. 
 Innovation in the pharmaceutical industry is extremely costly, this creates 
a major bias for pharmaceutical companies when deciding which drugs to 
research and develop.  To increase their chances of generating a greater profit, 
pharmaceutical companies spend money on researching and developing drugs 
that are oriented to the developed world.  There is no monetary incentive to 
improve global health when using the current patent system.  People living in the 
developed world are usually in the financial position to pay the market price for 
pharmaceuticals where those living in the underdeveloped world are not in the 
financial position to pay the market price for pharmaceuticals.  The developing 
world is greatly affected by life-threatening diseases and serious illness; it makes 
up for 90% of the world’s global burden of disease where the developed world 
only accounts for 10% of the global burden of disease.20  In order for 
pharmaceutical companies to innovate in a way that would be considered fair 
and just according to Rawls, it would be required to better the positions of those 
in the worst off positions.  Unequal distribution of research and development 
spending, in a way that increases the research and development of 
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pharmaceutical products oriented towards the developing world is what would be 
required for justice.  Spending that would match the global burden of disease, 
having 90% of pharmaceutical spending go towards 90% of the global burden of 
disease in the developing world would benefit those in the worst off position in 
the global society.   
 The final major area that would be considered unjust in the current patent 
system would be the overall spending efficiency.  In terms of overall spending 
efficiency the current patent system spends a large portion of sales revenue and 
funding on lobbying, gaming, patenting, litigation, marketing, and counterfeiting 
instead of spending of on research and development.  The current patent system 
allows for the possible rewarding of this behavior and spending, which can be 
considered wasteful.   This wasteful spending may lead to more income for 
pharmaceutical companies in some cases however, this does not guarantee 
more innovation or drugs being developed as a result.  Instead of spending 
money on wasteful activities, a new system would need to be in place that does 
not reward this type of spending and that promotes spending more of the sales 
revenue on research and development of new drugs.  Preferably having 
spending oriented towards developing drugs oriented toward the underdeveloped 
world where the greater burden of disease is accounted for would make for a 
more just system.     
 Overall, the major differences between the current patent system and with 
a system one might see behind the veil of ignorance is making drugs more 
universally accessible and affordable, having a system that does not create 
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biases for innovation unless it benefits those in the worst off positions, and for 
pharmaceutical companies to spend more efficiently; less on wasteful activities 
and more on research and development.  According to Rawlsian justice, these 
problems are the main reasons why the current patent system is unjust.                        
 
Big Pharma: Studies and Statistics 
 A study done by York University researchers estimates that the U.S 
Pharmaceutical industry spends almost twice as much on promotion, including 
advertising then it spends on the research and development of new drugs.  Marc-
Andre Gagnon and Joel Lexchin conducted the study concluding from their 
findings that there is a need for change in the priorities of the U.S pharmaceutical 
industry.  The data used was collected directly from the industry and from doctors 
in 2004.  IMS Health and CAM Group reports were examined.  These are 
international market research companies that provide the pharmaceutical 
industry with sales and marketing data and consulting services.  IMS Health 
interviews pharmaceutical firms where CAM Group surveys doctors.  Because 
the two firms use different methods for gathering data this allowed Gagnon and 
Lexchin to triangulate their estimations. This data shows the U.S pharmaceutical 
industry spent 24.4% of their income from sales on promotion, and only 13.4% of 
the income from sales on research and development.  In 2004 the total domestic 
sales for pharmaceuticals in the United States was $235.4 billion.   Although this 
study only included the U.S pharmaceutical industry, it still shows the depth of 
the problem.  The U.S has the largest market for pharmaceuticals in the world 
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representing 43% of global sales and promotion expenditures.  The researchers 
also note that the number of meetings for promotional purposes has dramatically 
increased in the U.S pharmaceutical industry.  In 1998 the number of meetings 
for promotional purposes was 120,000, and increased to 371,000 in 2004.  
These statistics and analysis show the pharmaceutical industry is market driven 
which takes away from the perception of a research drive, life saving, 
pharmaceutical industry.21   
 Many studies have found that the pharmaceutical industry in North 
America spends about twice as much on promotion and advertising than on 
research and development.  What is also important to research is what kind of 
drugs the research and development spending is being used to for and if the data 
supports a bias in what kind of drugs are being developed.  In Canada the 
average cost to develop a new medicine is $1.3 billion and $800 million in the 
United States.  These are statistics often used by pharmaceutical companies in 
order to justify their need for promotion and advertisement spending, however, 
the cited sources for this figure is a 2001 report from the Tufts Center for the 
Study of Drug Development, which happens to receive 65% percent of its funding 
from drug companies.  Most industry analysts, who do not typically receive 
funding from Big Pharma companies, believe these figures are exaggerated.  It is 
estimated that the $800 million dollar figure is used to describe only a minority of 
the most expensive drugs.  The Tufts analysis also included the “capital cost” 
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within the figures, that is, the out of pocket cost plus the estimated revenue that 
may have been generated if the money spent on research and development had 
instead been invested in the equity market.  Another problem with this estimated 
cost of developing a new drug is that it is in pre-tax dollars; research and 
development costs are fully tax deductible.   
 The 2006 Annual Report of the Patented Medicine Prices Review Board 
(PMPRD) showed that from 2000 until 2006 the Canadian pharmaceutical 
industry’s research and development-to-sales ratio was below what the industry 
had promised when the Mulroney government passed Bill C-22.  In 1987 the 
Patent Act was adopted where Canada’s Research Based Pharmaceutical 
Companies made a public commitment that brand name manufacturers would 
increase their annual research and development expenditure to 10% of sales 
revenue.  In 2006 only 8.1% of pharmaceutical sales revenue was spent on 
research and development in Canada.  This 8.1% also includes research 
expenditure funded by government grants.   
 In 2006 there were 99 new-patented medicines.  Of the 99 some are new 
presentations of existing medicines and 24 of the new-patented medicines were 
new active substances.  Of the 24 new active substances only 4 were Category 
2, which PMPRD defines as the first drug to treat effectively a particular disease 
or illness or which provides substantial improvement over existing drugs.  One 
would be able to conclude from this information that the majority of spending on 
research and development is not put towards generating new medicines but put 
towards developing a variation of a drug similar to an existing drug already on the 
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market.  Canadians alone spend $17.8 billion annually on prescription drugs.  If 
more of the sales revenue was put towards research and development it is likely 
more drugs would be developed and people who need these new drugs would 
buy them generating more sales revenue.22      
 In 1990 the Commission on Health Research and Development (CHRD) 
estimated that in 1986 out of the US$30 billion of health research worldwide only 
US$1.6 billion was relevant to the needs of developing countries, this is only 5% 
of all health research.  In 1996 the Ad Hoc Committee on Health Research 
Relating to Future Intervention Options published a study of spending on health 
research and development in 1992.  It was estimated in this report that there was 
a global investment of US$55.8 billion for pharmaceutical research and of this the 
amount devoted to health problems of developing countries was US$2.4 billion or 
4.3% of spending.  The CHRD estimated that 93% of the world’s burden of 
preventable mortality occurs in the developing world yet only 5% of research was 
devoted specifically to health problems of developing countries.23 
 
Thomas Pogge and the Health Impact Fund 
 As previously mentioned, the present patent system does a poor job at 
providing universal access to drugs.  Universal access is gravely undermined, 
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even in affluent countries, by extremely high mark-ups and, after the patent 
period, by inadequate incentives for the competent provision of generics to poor 
or hard-to-reach patients.  The existing patent system has focused innovation 
which is distorted by huge economic inequalities which allow for the rewards for 
“blockbuster drugs” and the 10/90 gap, a term coined by the Global Forum for 
Health Research in 1998.  The 10/90 gap refers to the statistic that 10 percent of 
money spent on all pharmaceutical research is used on diseases that affect 90 
percent of the global burden of disease and vice versa, where 90 percent of the 
money spent on all pharmaceutical research goes towards diseases that affect 
10 percent of the global burden of disease.24  Thomas Pogge, a philosopher and 
Health Impact Fund advocate, claims that the problem of innovation and access 
can be attributed to the unequal distribution of money in the world.  Those 
working within the pharmaceutical industry will look towards this distribution of 
money and cater to those who have the most money in order to be more 
profitable.  Within the current patent system companies make their money 
through patent protected mark-ups.  Overall efficiency is greatly diminished by 
lobbying, gaming, patenting and litigation, by deadweight losses, and by 
incentives for wasteful marketing and counterfeiting.  A lot of money goes to 
lobbying politicians to extend patent periods and to gaming, which includes name 
brand companies paying generic companies to delay putting their product on the 
market as well as litigation.  A lot of the profits pharmaceutical companies make 
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are going towards these activities, which Pogge considers wasteful.  Other 
wasteful activities performed by these companies include advertising and 
marketing, what one company spends on getting consumers to switch to their 
drug another company will spend in order to get those consumers back.   
 A common solution thought to fix these problems is to have a moral 
pressure placed on pharmaceutical companies; like individuals, pharmaceutical 
companies have duties of rescue, this may mean for them providing important 
drugs at an affordable cost to poor patients and to develop new medicines to 
help the poor.  Pogge does not believe this is the solution to the problems with 
the existing patent system but that it is in fact unrealistic to expect 
pharmaceutical companies to act on the same moral scale as individuals.  This is 
because pharmaceutical companies are bound to their shareholders; they are 
operating in a competitive market and rely on the sustainability of their innovation 
efforts, which is dependent on mark-ups.  The companies would not be 
successful if they did not make money for their shareholders, if they did not 
remain competitive in the market and did not place mark-ups on their products.   
 These problems with the current patent system, believed by many, are the 
main problems addressed by the Health Impact Fund.  What the Health Impact 
Fund is trying to adjust in the new pharmaceutical patent system is to make 
drugs more affordable and accessible to those in the underdeveloped world and 
to also try and eliminate the bias which drives pharmaceutical companies to 
develop first world drugs over third world drugs.  The HIF would incentivize the 
development and delivery of new medicines by paying for performance.  
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Performance in this case is referring, to what scale a specific drug effects health.  
If a drug makes a large impact on peoples lives, in the sense that it gives people 
with a specific disease a certain amount of added years onto their life or if it 
successfully treats a severe illness, then the inventor of that drug will receive 
money from the HIF if the inventor has registered with them.  The larger the 
impact, the larger the sum of money the inventor receives.  All pharmaceutical 
firms worldwide would have the option of registering new medicines with the HIF. 
By registering, a firm agrees to provide its drug at cost anywhere it is needed, 
and in exchange for foregoing the normal profits from drug sales.  The firm is 
rewarded based on the HIF’s assessment of the actual global health impact of 
the drug. Governments and other donors would finance the HIF.   
What is expected is that governments take money that would have already 
been allocated to the research and development of pharmaceuticals and put a 
percentage of this toward the HIF.  This system still provides the incentive to 
innovate and also puts the drive behind this industry back to improving global 
health rather than financial gain.  This system is thought to be more just in terms 
of Rawlsian justice.  Those companies who register through the HIF are paid 
based on how much of an impact their drug has made.  This creates a greater 
incentive to research and develop a drug that would be oriented towards 
underdeveloped countries, since they have more life threatening and widespread 
diseases.  It is likely a drug oriented to developing countries would be more 
profitable for pharmaceutical companies.  The system the HIF proposes also 
provides incentive for innovators to ensure the consumers of their 
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pharmaceutical products are taking the drugs properly.  When the drugs are 
taken properly they would be more effective, therefore, possibly generating a 
greater profit for the pharmaceutical company.  To guarantee the people are 
taking the drugs properly, companies may have labels or directions printed in 
local languages where the drugs are being sent to or other precautions similar to 
this.  This is not only beneficial to the pharmaceutical companies but to the 
consumers, it is possible that there would be fewer deaths due to taking 
medicines incorrectly, and the drugs would be more effective when taken 
properly. 25    
 The Health Impact Fund fulfills all of the areas that the current patent 
system is lacking.  In terms of Rawlsian justice the HIF proposes a system to 
fund research and development that provides incentive to innovate while 
providing universal access, promoting innovation that is not biased towards the 
developed world, and overall spending would be efficient. The Health Impact 
Fund is not meant to replace the current patent system but to provide an option 
to pharmaceutical companies to register with the HIF instead of using the current 
patent system.  It would be too difficult to replace the current patent system 
seeing as it is too embedded in the pharmaceutical industry to be replaced.    
Conclusion 
            Through my thesis I have shown that the current patent system, while 
having some virtues, providing an incentive for specific innovation and having 
effected global health, it is unjust according to Rawlsian justice for several 
reasons.  What justice would require according to the Rawlsian methodology for 
the pharmaceutical industry is that it provides universal access to drugs, 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
25 The Health Impact Fund, 2013, <http://healthimpactfund.com/> 
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innovation is not biased unless it is in a way that betters the positions of those in 
the worst off positions in society, and there is overall spending 
efficiency. Unfortunately, through my research I have found that the current 
patent system does not hold these characteristics that Rawlsian justice would 
require for the pharmaceutical industry.  The current patent system provides little 
or no incentive for pharmaceutical companies to provide products to poor people 
in the hard-to-reach developing world.  People in the developing world are often 
unable to afford the market price of pharmaceutical products; therefore, 
pharmaceutical companies do not make the drugs accessible in these developing 
areas because there is no profit to be made by doing this.  Innovation as well as 
research and development is extremely costly in the pharmaceutical industry.  In 
order to fund their research and development pharmaceutical companies 
generate the largest profits by developing “blockbuster” drugs that are oriented 
toward the developed world.  This creates biased innovation that disfavours 
those living in the underdeveloped world.  Companies will not develop drugs 
oriented towards the developing world because it is likely through the current 
patent system that it will not be profitable.  Lastly, the current patent system 
spends the majority of its sales revenue on wasteful activities on marketing and 
promotion instead of spending more on research and development.  
After finding that the current patent system is unjust and in what ways it is 
unjust, I explored the proposal of the Health Impact Fund.  The HIF puts forward 
a new way to fund research and development for pharmaceutical companies 
while holding the characteristics for justice the Rawlsian methodology 
requires.  The HIF would incentivize the development and delivery of new 
medicines by paying for performance; this means a pharmaceutical company 
would be paid based on a scale of how much their specific drug registered with 
the HIF makes a positive impact on global health.  By registering with the HIF 
companies would forego the normal profits from the current patent system and 
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make available their drug anywhere it is needed at cost.  This solves the problem 
the current patent system has with universal access.  Innovation would likely be 
focused on life-threatening diseases and diseases in the developing world 
because the potential for improving global health is greater if a cure is found for 
these illnesses, generating a greater profit for pharmaceutical companies.  There 
would be no need for the marketing and promotion of “blockbuster” drugs when 
the focus is on the improvement of global health. The system the HIF proposes 
would provide universal access, innovation that is not biased unless it benefits 
those in the worst off positions in society, and overall spending efficiency.  
The HIF is a system that should be adopted because it provides a more 
just pharmaceutical industry and would improve overall global health.  The drive 
behind the pharmaceutical industry would no longer be marketing and profits 
from drugs that are only slight variation of already existing drugs, but on the 
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